Docivyx Injection, Solution
Product Images NDC 83831-103

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docivyx (NDC 83831-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel-structure (2ad4f265 675e 47bf A2fa 57d9266a6dda 01)

Chemical structure of docetaxel, a complex molecular diagram showing its detailed atomic composition and arrangement, including multiple rings, hydroxyl, methyl, and carbonyl groups, and three water molecules indicating hydration.*

FDA Label Image

Figure 1: Tax316 Disease-free Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 02)

A Kaplan-Meier survival curve chart showing Disease-Free Survival (DFS) Probability (%) on the vertical axis versus Disease-Free Survival Time (months) on the horizontal axis, comparing two groups labeled TAC and FAC over a period of up to 66 months.*

FDA Label Image

Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 03)

A survival probability Kaplan-Meier plot showing survival probability (%) versus survival time in months. Two survival curves are compared: one labeled TAC (solid line) and one labeled FAC (dotted line), both illustrating changes in survival probability over time up to about 66 months.*

FDA Label Image

Figure 3: Tax317 Survival K-m Curves (DOCIVYX 75 mg/m2 Versus Best Supportive Care)

A Kaplan-Meier survival curve chart depicting overall survival probability over time in months. Two groups are compared: T75 (solid line) and BSC (dashed line). The y-axis shows cumulative probability from 0 to 1, and the x-axis covers survival time up to 21 months. A log-rank p-value of 0.010 is noted, indicating statistical comparison between the groups.*

FDA Label Image

Figure 4: Tax320 Survival K-m Curves (DOCIVYX 75 mg/m2 Versus Vinorelbine or Ifosfamide Control)

A Kaplan-Meier survival curve chart showing cumulative probability versus survival time in months. Two treatment groups, labeled T75 and V/I, are compared for overall survival with a log-rank p-value of 0.13. The x-axis measures survival time up to about 21 months, and the y-axis measures cumulative probability from 0 to 1.0.*

FDA Label Image

Figure 5: Tax327 Survival K-m Curves (2ad4f265 675e 47bf A2fa 57d9266a6dda 06)

A Kaplan-Meier survival curve chart displaying survival probability over time in months. Two curves are shown: a solid line labeled 'T75 q3w' and a dashed line labeled 'M q3w,' indicating different treatment groups or doses. The y-axis represents survival probability from 0 to 1, and the x-axis shows survival time up to 30 months.*

FDA Label Image

Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 07)

A line chart showing probability (%) on the y-axis versus time in months on the x-axis, with two curve lines labeled TCF (solid line) and CF (dotted line). The chart compares probability trends for the two groups over a 24-month period, starting near 100% at month 0 and decreasing over time.*

FDA Label Image

Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 08)

A survival curve chart displaying survival probability (%) versus survival time in months. Two lines represent different groups labeled TCF (solid line) and CF (dotted line), showing comparative survival over a 36-month period.*

FDA Label Image

Figure 8: Tax323 Progression-free Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 09)

A Kaplan-Meier curve chart showing progression-free survival (PFS) probability over time in months. The y-axis represents PFS probability in percentage, and the x-axis shows progression-free survival time in months up to 42 months. The chart compares two groups labeled TPF and PF with separate survival curves.*

FDA Label Image

Figure 9: Tax323 Overall Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 10)

A survival probability chart comparing two groups labeled TPF and PF over a survival time of 0 to 72 months. The Y-axis shows survival probability as a percentage from 0 to 100%, and the X-axis indicates time in months. The TPF group shows higher survival probability over time compared to the PF group.*

FDA Label Image

Figure 10: Tax324 Overall Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 11)

A survival probability Kaplan-Meier plot showing survival time in months on the x-axis and survival probability percentage on the y-axis. Two groups, TPF (n=255) and PF (n=246), are compared with solid and dashed lines respectively. A table below the graph lists the number of patients at risk over time for each group.*

FDA Label Image

Docivyx (docetaxel) Injection, 20 mg/2 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 12)

Label for Docivyx (docetaxel) Injection showing the 20 mg per 2 mL strength (10 mg per mL concentration). It is for intravenous infusion only, in a 2 mL single-dose vial. The label includes a warning for hazardous drug, storage instructions, manufacture details by Avyxa Pharma, LLC, and barcodes.*

FDA Label Image

Docivyx (docetaxel) Injection, 20 mg/2 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 13)

Packaging label for Docivyx (docetaxel) Injection, 20 mg per 2 mL (10 mg per mL) solution for intravenous infusion, single-dose vial. Label shows active ingredients, storage instructions, warnings including hazardous drug caution, manufacturer Avyxa Pharma, LLC, along with NDC number 83831-101-02 and barcode.*

FDA Label Image

Docivyx (docetaxel) Injection, 80 mg/8 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 14)

Label for DOCIVYX (docetaxel) Injection, 80 mg per 8 mL (10 mg per mL), intravenous infusion solution. The label indicates the product is an 8 mL single-dose vial for intravenous use, with instructions to discard unused portions. Manufactured by Avyxa Pharma, LLC, New Jersey, USA, with storage instructions at 2°C to 25°C and protection from light. The label includes hazard warnings and barcodes.*

FDA Label Image

Docivyx (docetaxel) Injection, 80 mg/8 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 15)

Packaging label for Docivyx (docetaxel) Injection, 80 mg per 8 mL (10 mg per mL) solution. The label indicates it is a single-dose vial for intravenous infusion, manufactured for Avyxa Pharma, LLC. It includes storage instructions, a warning that it is a hazardous drug, and directions to discard unused portions.*

FDA Label Image

Docivyx (docetaxel) Injection, 160 mg/16 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 16)

Label for Docivyx (docetaxel) Injection, 160 mg per 16 mL (10 mg per mL) intravenous infusion solution. The label warns it is a hazardous drug and provides storage instructions to protect from light at 2°C to 25°C. It is manufactured by Avyxa Pharma, LLC, New Jersey, USA, and labeled as a single-dose vial with discard instructions for unused portions.*

FDA Label Image

Docivyx (docetaxel) Injection, 160 mg/16 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 17)

Label for DOCIVYX (docetaxel) Injection, solution for intravenous infusion, 160 mg per 16 mL (10 mg per mL). The label states it is ready to add to infusion solution, supplied as a single-dose vial, and includes warnings about it being a hazardous drug. Manufactured for Avyxa Pharma, LLC, with storage instructions and ingredient details listed.*

FDA Label Image

Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 187 2)

FDA Label Image

Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 213 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.